🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million instances annually. Notably increased rates are observed in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was authorized by the American regulatory agency in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is also used to treat urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the drug firm its industry partner to develop it.

“This approval represents a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Results and Worldwide Availability

Based on results detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The trial involved hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of regions with limited resources.

Doctors directly involved have expressed hope. The availability of a one-pill regimen like this is hailed as a "critical tool" for public health efforts. This is deemed essential to alleviate the strain of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.